Good Quality Locally Procured Drugs Can Be as Effective as Internationally Quality Assured Drugs in Treating Multi-Drug Resistant Tuberculosis

Abstract

BackgroundOwing toGiven the high costs of drugs to treat multi-drug resistant tuberculosis (MDR-TB), the Green Light Committee (GLC) initiative enables TB programs to procure quality-assured drugs at reduced prices. Despite price reductions, internationally quality assured (IQA) drugs can be more expensive than locally procured drugs. There is little evidence to inform decision-makers about whether IQA drugs are more effective than local drugs. This is the first study to compare outcomes between MDR-TB patients treated using IQA, and locally procured drugs in the same hospitals during the same time period.Methods/FindingsA retrospective cohort study was conducted in three hospitals across Pakistan. Data on baseline characteristics and treatment outcomes during the first six months of treatment were extracted from hospital records of adult culture-positive pulmonary MDR-TB patients starting treatment between January 2011 and June 2012. Two cohorts were defined: patients receiving IQA drugs, and patients receiving locally procured non-IQA drugs. Data were analysed using Kaplan-Meier curves and Cox proportional hazards regression. The primary outcome compared between cohorts was time to culture conversion. Of 231 patients, 90 were in the IQA and 141 in the non-IQA cohorts. Baseline characteristics were similar except for higher frequency of quinolone resistance in the IQA cohort. Overall, 193 patients (84%) culture converted. Culture conversion was not faster in the IQA cohort; the median time was 81 and 68 days in the IQA and non-IQA cohorts, respectively. Unadjusted and adjusted hazard ratios for culture conversion in IQA verses non-IQA cohorts were 0.82 (95%-CI, 0.62-1.10) and 0.95 (95%-CI, 0.66-1.36) respectively.ConclusionsUse of good quality, locally procured drugs can be effective in treating MDR-TB, may involve lower costs than using IQA drugs and could strengthen developing country drug quality assurance systems. This may be a suitable alternative in lieu of or whilst awaiting arrival of internationally procured medicines.

High use of private providers for first healthcare seeking by drug-resistant tuberculosis patients: a cross-sectional study in Yangon, Myanmar

“…The most likely main determinant of switching to the public sector after diagnosis with DR-TB is the high cost of future visits in the private sector, because DR-TB requires expensive medication [ 27 , 28 ]. A study in Cambodia also found that patients would initially visit private healthcare providers and switch to the public sector once they knew they had TB, because they wanted to access free TB treatment which would not be available in the private sector [ 29 ].…”

Recent and New Strategies for Extensively-Drug Resistant Tuberculosis

“…An improved drug-resistant TB control program may require new drugs, which are very expensive. Diagnostic tests, hospitalization, direct expenses to the patient, and follow-up monitoring should be considered from this point of view [7,[83][84][85][86][87] .…”

Regulatory framework in Pakistan: situation analysis of medicine quality and future recommendations

“…The WHO prequalification program was adopted [50] and accepted countrywide by a number of organizations improving the delivery of quality medicines. In a local study, no significant benefit was found in terms of time taken for smear conversion for the 15–20% more expensive internationally quality assured medicines when compared with locally produced multiple drug resistant tuberculosis medicines purchased through the medicine prequalification program [51]. In this way, the new control strategies have evolved, involving the interventions at system level rather than being limited to punishments and penalties.…”